News

The pharma company had also received £1m from the government agency for the development of novel meningococcal B vaccine, MenBioVax in late 2012. ImmBio’s vaccine candidates are based

The lymphatic mapping procedure identifies and biopsies lymph nodes that may contain tumor metastases and determine if cancer has spread beyond the primary tumor. Lymphoseek is a receptor

Under the agreement, Focus Diagnostics will gain the global rights to integrate HyBeacons PCR probe technology into its molecular diagnostic products and services. HyBeacons probes are sequence specific

LIPO-202 is an injectable pharmaceutical designed to produce aesthetic reduction of subcutaneous abdominal fat. Lithera president and CEO George Mahaffey said, "Following our recent Series C financing, Lithera

As per the agreement, Receptos will lead a Phase 2 clinical study to demonstrate proof-of-concept in Eosinophilic Esophagitis (EoE), an indication designated as an Orphan Disease by the

The company has developed NT0202, leveraging its extended-release technology, as a treatment to attention deficit hyperactivity disorder (ADHD) and is requesting for manufacturing and marketing approval of the

MK-8931 is an oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor. Under the agreement, Luminex will leverage xMAP technology in developing the candidate device to measure

Dymista is indicated for patients 12 years of age and older who require treatment with both azelastine hydrochloride and fluticasone propionate for symptomatic relief. The new nasal spray

Dr Ramachandra served as senior vice president, R&D, regulatory and medical affairs, and chief scientific officer of Hospira. Prior to Hospira, he served as vice president and oncology